Literature DB >> 29423673

Stromal expression of JNK1 and VDR is associated with the prognosis of esophageal squamous cell carcinoma.

Y Bao1, S Zhang2, Y Guo1, X Wei1, Y Zhang2, Y Yang1, H Zhang2, M Ma3, W Yang4,5.   

Abstract

PURPOSE: Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide, and its outcome is poor. The purpose of this study was to determine the association between JNK1 and vitamin D receptor (VDR) expression and the prognosis of ESCC.
METHODS: Immunohistochemical staining was conducted on ESCC tissue microarrays (362 pairs of ESCC and normal esophagus tissues). The epithelial and stromal expression levels of c-jun NH2-terminal kinase 1 (JNK1) and VDR were scored and correlated with the ESCC characteristics. Laser-capture-based quantitative RT-PCR was performed on ESCC tissues. The effects of JNK1 and VDR on ESCC cell proliferation and migration were analyzed in vitro by transient transfection, and protein changes were evaluated by immunoblotting.
RESULTS: Both JNK1 and VDR were reduced in ESCC epithelial cells in comparison with the normal esophagus, but the expression of JNK1 and VDR in ESCC stromal tissues, not epithelial cells, was strongly associated with the survival time of ESCC patients. Functional studies showed that increased JNK1 suppressed cancer cell proliferation, mobility, and migration, which were linked to the alterations of VDR and metastasis-associated proteins.
CONCLUSION: JNK1 and VDR act as tumor suppressors, and their stromal expression levels are associated with prognosis in esophageal squamous cell carcinoma.

Entities:  

Keywords:  Esophageal cancer; JNK1; Prognosis; Stroma; VDR

Mesh:

Substances:

Year:  2018        PMID: 29423673     DOI: 10.1007/s12094-018-1843-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  40 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance.

Authors:  Yunfei Gao; Jian Tao; Ming O Li; Dongqing Zhang; Hongbo Chi; Octavian Henegariu; Susan M Kaech; Roger J Davis; Richard A Flavell; Zhinan Yin
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

Review 3.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  Cancer chemoprevention using natural vitamin D and synthetic analogs.

Authors:  K Z Guyton; T W Kensler; G H Posner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 5.  Vitamin D and colon carcinogenesis.

Authors:  Diane M Harris; Vay Liang W Go
Journal:  J Nutr       Date:  2004-12       Impact factor: 4.798

6.  c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression.

Authors:  Chang Tong; Zhinan Yin; Zibo Song; Ashley Dockendorff; Chuanshu Huang; John Mariadason; Richard A Flavell; Roger J Davis; Leonard H Augenlicht; Wancai Yang
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

7.  Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells.

Authors:  Shiro Fukumori; Toshiya Murata; Masato Taguchi; Yukiya Hashimoto
Journal:  Drug Metab Pharmacokinet       Date:  2007-10       Impact factor: 3.614

8.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.

Authors:  Lijian Hui; Kurt Zatloukal; Harald Scheuch; Ewa Stepniak; Erwin F Wagner
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

9.  Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.

Authors:  H G Pálmer; J M González-Sancho; J Espada; M T Berciano; I Puig; J Baulida; M Quintanilla; A Cano; A G de Herreros; M Lafarga; A Muñoz
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

Review 10.  Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer.

Authors:  Upasana Bedi; Vivek Kumar Mishra; David Wasilewski; Christina Scheel; Steven A Johnsen
Journal:  Oncotarget       Date:  2014-04-30
View more
  6 in total

1.  Influence of vitamin D on cancer risk and treatment: Why the variability?

Authors:  M Rita I Young; Ying Xiong
Journal:  Trends Cancer Res       Date:  2018

2.  The voltage-gated sodium channel Nav1.7 associated with endometrial cancer.

Authors:  Junxiu Liu; Hao Tan; Wancai Yang; Shuzhong Yao; Liang Hong
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

3.  Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3.

Authors:  Zixian Huang; Yin Zhang; Haigang Li; Yufeng Zhou; Qianyu Zhang; Rui Chen; Tingting Jin; Kaishun Hu; Shihao Li; Yan Wang; Weiliang Chen; Zhiquan Huang
Journal:  Cell Death Dis       Date:  2019-12-09       Impact factor: 8.469

4.  BAG2 Overexpression Correlates with Growth and Poor Prognosis of Esophageal Squamous Cell Carcinoma.

Authors:  Ying-Cai Hong; Zheng Wang; Bin Peng; Li-Gang Xia; Lie-Wen Lin; Zheng-Lei Xu
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

5.  Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study.

Authors:  Stephen McCain; James Trainor; Damian T McManus; Úna C McMenamin; Stephen McQuaid; Victoria Bingham; Jacqueline A James; Manuel Salto-Tellez; Richard C Turkington; Helen G Coleman
Journal:  Oncotarget       Date:  2018-09-28

6.  Distribution of esophagus flora in esophageal squamous cell carcinoma and its correlation with clinicopathological characteristics.

Authors:  Mengcheng Hu; Wenxia Bai; Chengcheng Zhao; Jianning Wang
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.